ESMO Breast 2025 | Phase II trial of T-DM1 and palbociclib in metastatic HER2+ breast cancer
Pavani Chalasani, MD, MPH, The George Washington University, Washington, DC, discusses results from a Phase II study (NCT03530696) of trastuzumab emtansine (T-DM1) with palbociclib in metastatic HER2+ breast cancer. The trial, initially randomized, was modified to a single-arm design due to low accrual. The combination showed longer progression-free survival and higher response rates compared to historical data for T-DM1 alone, with consistent outcomes across estrogen receptor subtypes. No new safety concerns emerged, and the findings support further investigation in a larger randomized setting. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
